8-K: Cosmos Health Unveils $300M Digital Treasury, US Expansion

Cosmos Health Inc. announced its CEO's annual letter detailing a $300 million digital asset financing facility, U.S. manufacturing expansion, and AI innovation for global healthcare growth.

Summary

• The Chief Executive Officer's annual letter for the year ended December 31, 2024, was made available on September 29, 2025.
• A $300 million senior secured convertible promissory note facility was secured from a U.S. institutional investor in August 2025.
• 72.5% of net proceeds from the financing facility will be directed towards building a digital treasury reserve, including Ethereum (ETH), Bitcoin (BTC), and Solana (SOL), with capacity to invest over $200 million in digital assets.
• The remaining capital from the facility will be allocated to working capital and accelerating growth initiatives, both organic and through acquisitions.
• Phase I upgrades at Cana Laboratories in Athens, Greece, were completed in 2024, with these investments expected to generate over $10 million in recurring annual gross profit at full capacity.
• U.S.-based GMP-certified production was established in 2025 through a partnership with NOOR Collagen, expanding the global manufacturing footprint.
• Sky Premium Life, the flagship nutraceutical brand, added over sixty new formulations in 2025, bringing its portfolio to over 150 premium products.
• U.S. operations for Sky Premium Life, launched with NOOR Collagen, are projected to generate over $12 million in annualized revenue at approximately 75% gross margins.
• CosmoFarm, the wholesale and logistics arm, achieved record revenue of approximately $43 million in the first ten months of 2024, an 8.62% increase over the same period in 2023.
• CosmoFarm's gross profit rose by 21% in the first ten months of 2024 and is projected to surpass $50 million in annualized revenue.
• The proprietary obesity treatment, CCX0722, has advanced beyond laboratory development into the clinical trial preparation stage, with a potential launch as early as 2026.
• A 10-drug generics portfolio was acquired in 2024, diversifying the company's pharmaceutical offerings.
• Revenues increased to $54.43 million in 2024, an approximately 2% gain over 2023.
• Operating expenses decreased by approximately 24% year over year in 2024, with general and administrative costs down 40% and sales and marketing down 71%.
• Adjusted EBITDA was ($3.73 million) in 2024, compared to a small gain in 2023, primarily due to increased investments.
• Net loss widened to ($4.74 million) in 2024.
• Total assets were $54.31 million and equity was $24.53 million at year-end 2024.
• Revenue in H1 2025 was $28.46 million, an increase of 11.7% compared to $25.49 million in H1 2024.
• Gross profit rose to $3.21 million in H1 2025, up 53% year over year.
• Total assets were $61.84 million as of June 30, 2025, up 13.9% from $54.31 million at year-end 2024.
• Stockholders' equity was $26.23 million as of June 30, 2025, compared to $24.53 million at year-end 2024.
• Liabilities were $35.60 million as of June 30, 2025, resulting in a liabilities-to-assets ratio of approximately 57.6%.
• CEO Greg Siokas has personally invested over $18 million into the company and holds over 6 million shares.

Sentiment

Score: 8

Explanation: The CEO letter conveys a highly optimistic outlook, highlighting substantial strategic achievements like the $300 million digital asset facility, significant manufacturing expansion, strong brand growth, and promising R&D. While 2024 saw a net loss, H1 2025 shows strong revenue and gross profit growth, coupled with disciplined cost management. The CEO's personal investment further reinforces confidence, indicating a strong positive trajectory and strategic execution.

Positives

• Secured a substantial $300 million digital asset financing facility, providing significant capital for growth initiatives and establishing a robust digital treasury reserve.
• Successfully expanded manufacturing capabilities with the completion of Phase I upgrades at Cana Laboratories in Greece and the establishment of new U.S. GMP-certified production.
• Achieved strong growth and international expansion of the Sky Premium Life nutraceutical brand, including projected annualized revenue of over $12 million from U.S. operations at approximately 75% gross margins.
• CosmoFarm wholesale business delivered record performance in the first ten months of 2024, with an 8.62% revenue increase and a 21% gross profit rise.
• Made significant progress in R&D, advancing the proprietary obesity treatment CCX0722 to clinical trial preparation and expanding oncology and CNS pipelines using AI-driven discovery.
• Diversified the product portfolio with the acquisition of a 10-drug generics portfolio in 2024.
• Demonstrated revenue growth in 2024 (2% increase) and accelerated growth in H1 2025 (11.7% increase).
• Implemented effective cost-cutting measures in 2024, leading to a 24% decrease in operating expenses, including a 40% reduction in G&A and a 71% reduction in sales and marketing costs.
• Achieved a substantial 53% year-over-year increase in gross profit in H1 2025.
• Strengthened the balance sheet with a 13.9% increase in total assets and an improved stockholders' equity position in H1 2025.
• The CEO's significant personal investment of over $18 million and ownership of over 6 million shares demonstrates strong insider conviction and alignment with shareholder interests.
• Secured long-term contract manufacturing agreements for Cana Laboratories, providing revenue visibility and stability.

Negatives

• Adjusted EBITDA was negative ($3.73 million) in 2024, a decline from a small gain in 2023, primarily attributed to increased investments in facilities and R&D.
• Net loss widened to ($4.74 million) in 2024.
• The digital asset treasury strategy, while innovative, introduces exposure to the inherent volatility of digital asset markets.

Risks

• Forward-looking statements are not guarantees of future performance, and there is no assurance that the company will execute its anticipated strategic plans or realize expected outcomes.
• Future results, financial condition, and business may differ materially from those expressed in forward-looking statements.
• The company's ability to raise sufficient financing to implement its business plan is a risk factor.
• The effectiveness of its digital asset strategies, including accumulation and yield-generating activities, is subject to market and operational risks.
• The impact of the war in Ukraine on the company's business, operations, and the economy in general poses a risk.
• The company's ability to successfully develop and commercialize its proprietary products and technologies is not guaranteed.

Future Outlook

Cosmos Health aims to transform into a global powerhouse by 2030, scaling branded products, deepening its scientific pipeline, and leveraging AI and blockchain to redefine healthcare discovery and delivery. The company targets continued growth and profitability through 2027, with projected revenue of approximately $155.8 million and Adjusted EBITDA of $29.4 million, alongside achieving positive operating cash flow. Key initiatives include the launch of Cloudscreen 2.0 to enhance discovery, the potential 2026 launch of the proprietary obesity treatment CCX0722, and evaluating a potential spin-off of its R&D division.

Management Comments

• "Cosmos Health stands at a defining moment in its journey."
• "These achievements mark the beginning of a new era for Cosmos Health – one defined by growth, innovation, and resilience."
• "Our purpose is clear: to make high-quality healthcare accessible worldwide while driving innovation at the intersection of science, technology, and digital finance."
• "Looking ahead to 2030, our ambition is to transform Cosmos Health into a global powerhouse."
• "The Company doesn't view digital-asset treasury reserve as a speculative side venture; it is central to our broader vision."
• "We believe these investments position Cana to generate more than $10 million in recurring annual gross profit at full capacity."
• "In the opinion of the Company, our momentum has accelerated in 2025, reflecting the benefits of our strategic investments and the strength of our branded product portfolio."
• "As both CEO and a long-term shareholder, I want to emphasize my personal commitment. Since the inception of Cosmos Health, I have invested more than $18 million of my own capital into the Company, and I now hold over 6 million shares."
• "With your trust and support, I am confident that the momentum we are building today will translate into lasting value and enduring success in the years to come."

Industry Context

The healthcare industry is undergoing significant transformation, with increasing integration of digital finance, artificial intelligence, and blockchain technologies in drug discovery, intellectual property monetization, and corporate treasury management. Cosmos Health's strategic moves, including its substantial digital asset facility and AI-enabled R&D platforms, align with these broader industry trends. The company's focus on expanding its global footprint for nutraceuticals and pharmaceuticals, alongside strengthening contract manufacturing, positions it to capitalize on growing global demand and the increasing market for high-margin, vertically integrated healthcare solutions. The emphasis on obesity treatment and oncology addresses major global health challenges and significant market opportunities.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value through strategic growth initiatives, improved financial performance, and the CEO's significant personal investment aligning interests.
• Employees: Expansion of manufacturing facilities and business operations may lead to job creation, stability, and opportunities for professional development.
• Customers: Increased access to a broader portfolio of high-quality healthcare products, including pharmaceuticals, nutraceuticals, diagnostics, and hygiene solutions, globally.
• Suppliers: Potential for increased demand for raw materials, components, and services due to expanded manufacturing and distribution activities.
• Creditors: The $300 million financing facility and bond loan facility indicate increased debt, but are intended to support growth and strengthen the company's financial position.

Next Steps

• Maximize the impact of the $300 million digital asset facility through disciplined treasury management and by channeling resources into the continued growth of core healthcare businesses.
• Further expand output at Cana Laboratories through Phase II upgrades.
• Continue to develop and launch additional formulations for Sky Premium Life in 2026.
• Advance proprietary obesity treatment, CCX0722, through clinical trials for a potential launch as early as 2026.
• Expand oncology and CNS portfolios through new discoveries and licensing.
• Launch Cloudscreen 2.0 to enhance internal discovery and collaboration opportunities.
• Evaluate strategic options such as a potential spin-off of the R&D division.
• Pursue disciplined acquisitions and alliances to broaden distribution, technology, and branded products.
• Actively pursue a potential supply contract with the UK National Health Service (NHS) for C-Sept and C-Scrub.
• Achieve target revenue of approximately $155.8 million and Adjusted EBITDA of $29.4 million by 2027.
• Achieve positive operating cash flow as a central near-term milestone.

Key Dates

Recommendation

The filing details a robust strategic pivot and significant operational achievements, including a substantial $300 million financing facility that diversifies the balance sheet with digital assets while funding core growth. The company demonstrates strong momentum with 11.7% revenue growth and 53% gross profit increase in H1 2025, coupled with aggressive cost cutting in 2024. Expansion into U.S. manufacturing, global reach of Sky Premium Life, and a promising R&D pipeline (e.g., CCX0722) position Cosmos Health for substantial future growth. The CEO's personal investment of over $18 million and holding over 6 million shares signals strong insider confidence. The ambitious 2027 targets for revenue ($155.8M) and Adjusted EBITDA ($29.4M), alongside a clear path to positive operating cash flow, suggest significant upside potential for investors.

Keywords

Healthcare, Pharmaceuticals, Nutraceuticals, Digital Assets, AI Innovation, Manufacturing, R&D, Biotech, NASDAQ, COSM, Global Expansion, Corporate Treasury, Contract Manufacturing, Obesity Treatment, Oncology, Generics, Wholesale Distribution, Greece, USA